Employment, medical absenteeism, and disability perception in Parkinson's disease : A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy
Identifieur interne : 001B11 ( PascalFrancis/Checkpoint ); précédent : 001B10; suivant : 001B12Employment, medical absenteeism, and disability perception in Parkinson's disease : A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy
Auteurs : Alexei Korchounov [Allemagne, Égypte] ; Gregory Bogomazov [Russie]Source :
- Movement disorders [ 0885-3185 ] ; 2006.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
The objective of this study was to test the impact of entacapone (ENT) addition to levodopa with a decarboxylase inhibitor (LD) in full-time-employed patients with Parkinson's disease (PD), focusing on retirement rates, medical absenteeism, self-perception of disability, as well as motor assessments of parkinsonism, motor fluctuations, and dyskinesias. Thirty full-time-employed PD patients (disease onset before age 60 years) and on optimized monotherapy with LD exhibiting minor motor fluctuations or dyskinesias were entered into a 2-year randomized double-blind placebo-controlled study of ENT adjunctive therapy. The outcome measures were the number of full-time-employed patients at study end, cumulative days of medical absenteeism, patient-completed disability assessments, diary records, and the Unified Parkinson's Disease Rating Scale-based measures of motor fluctuations and dyskinesias. LD + ENT treatment was associated with a lower retirement rate (2 [17%] of 12 vs. 6 [50%] of 12; P = 0.12), lower absenteeism rate (21.5 vs. 43.5 days; P < 0.0001), improved self-perception of disability progression over 2 years (change score 1.0 vs. 4.5; P < 0.0001), and lower scores for both motor fluctuations and dyskinesia assessments compared to LD monotherapy. In this pilot study, LD with ENT adjunctive therapy positively influenced employment rate over 2 years; this effect was associated with reduced motor complications and patient perceptions of stabilized disability.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:07-0090884Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Employment, medical absenteeism, and disability perception in Parkinson's disease : A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy</title><author><name sortKey="Korchounov, Alexei" sort="Korchounov, Alexei" uniqKey="Korchounov A" first="Alexei" last="Korchounov">Alexei Korchounov</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Parkinson Clinic</s1><s2>Bad Nauheim</s2><s3>DEU</s3><sZ>1 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Bad Nauheim</wicri:noRegion><wicri:noRegion>Parkinson Clinic</wicri:noRegion><wicri:noRegion>Parkinson Clinic</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Hospital of Misr International University</s1><s2>Cairo</s2><s3>EGY</s3><sZ>1 aut.</sZ></inist:fA14><country>Égypte</country><wicri:noRegion>Hospital of Misr International University</wicri:noRegion></affiliation></author><author><name sortKey="Bogomazov, Gregory" sort="Bogomazov, Gregory" uniqKey="Bogomazov G" first="Gregory" last="Bogomazov">Gregory Bogomazov</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Center for Investigation of Movement Disorders</s1><s2>Moscow</s2><s3>RUS</s3><sZ>2 aut.</sZ></inist:fA14><country>Russie</country><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">07-0090884</idno><date when="2006">2006</date><idno type="stanalyst">PASCAL 07-0090884 INIST</idno><idno type="RBID">Pascal:07-0090884</idno><idno type="wicri:Area/PascalFrancis/Corpus">001855</idno><idno type="wicri:Area/PascalFrancis/Curation">001466</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001B11</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Employment, medical absenteeism, and disability perception in Parkinson's disease : A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy</title><author><name sortKey="Korchounov, Alexei" sort="Korchounov, Alexei" uniqKey="Korchounov A" first="Alexei" last="Korchounov">Alexei Korchounov</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Parkinson Clinic</s1><s2>Bad Nauheim</s2><s3>DEU</s3><sZ>1 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Bad Nauheim</wicri:noRegion><wicri:noRegion>Parkinson Clinic</wicri:noRegion><wicri:noRegion>Parkinson Clinic</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Hospital of Misr International University</s1><s2>Cairo</s2><s3>EGY</s3><sZ>1 aut.</sZ></inist:fA14><country>Égypte</country><wicri:noRegion>Hospital of Misr International University</wicri:noRegion></affiliation></author><author><name sortKey="Bogomazov, Gregory" sort="Bogomazov, Gregory" uniqKey="Bogomazov G" first="Gregory" last="Bogomazov">Gregory Bogomazov</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Center for Investigation of Movement Disorders</s1><s2>Moscow</s2><s3>RUS</s3><sZ>2 aut.</sZ></inist:fA14><country>Russie</country><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Disability</term><term>Double blind study</term><term>Dyskinesia</term><term>Entacapone</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Perception</term><term>Placebo</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term><term>Parkinson maladie</term><term>Dyskinésie</term><term>Incapacité</term><term>Perception</term><term>Etude double insu</term><term>Placebo</term><term>Entacapone</term><term>Traitement</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study was to test the impact of entacapone (ENT) addition to levodopa with a decarboxylase inhibitor (LD) in full-time-employed patients with Parkinson's disease (PD), focusing on retirement rates, medical absenteeism, self-perception of disability, as well as motor assessments of parkinsonism, motor fluctuations, and dyskinesias. Thirty full-time-employed PD patients (disease onset before age 60 years) and on optimized monotherapy with LD exhibiting minor motor fluctuations or dyskinesias were entered into a 2-year randomized double-blind placebo-controlled study of ENT adjunctive therapy. The outcome measures were the number of full-time-employed patients at study end, cumulative days of medical absenteeism, patient-completed disability assessments, diary records, and the Unified Parkinson's Disease Rating Scale-based measures of motor fluctuations and dyskinesias. LD + ENT treatment was associated with a lower retirement rate (2 [17%] of 12 vs. 6 [50%] of 12; P = 0.12), lower absenteeism rate (21.5 vs. 43.5 days; P < 0.0001), improved self-perception of disability progression over 2 years (change score 1.0 vs. 4.5; P < 0.0001), and lower scores for both motor fluctuations and dyskinesia assessments compared to LD monotherapy. In this pilot study, LD with ENT adjunctive therapy positively influenced employment rate over 2 years; this effect was associated with reduced motor complications and patient perceptions of stabilized disability.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>21</s2></fA05><fA06><s2>12</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Employment, medical absenteeism, and disability perception in Parkinson's disease : A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy</s1></fA08><fA11 i1="01" i2="1"><s1>KORCHOUNOV (Alexei)</s1></fA11><fA11 i1="02" i2="1"><s1>BOGOMAZOV (Gregory)</s1></fA11><fA14 i1="01"><s1>Parkinson Clinic</s1><s2>Bad Nauheim</s2><s3>DEU</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Hospital of Misr International University</s1><s2>Cairo</s2><s3>EGY</s3><sZ>1 aut.</sZ></fA14><fA14 i1="03"><s1>Center for Investigation of Movement Disorders</s1><s2>Moscow</s2><s3>RUS</s3><sZ>2 aut.</sZ></fA14><fA20><s1>2220-2224</s1></fA20><fA21><s1>2006</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000145356790340</s5></fA43><fA44><s0>0000</s0><s1>© 2007 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>16 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>07-0090884</s0></fA47><fA60><s1>P</s1><s3>CC</s3></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>The objective of this study was to test the impact of entacapone (ENT) addition to levodopa with a decarboxylase inhibitor (LD) in full-time-employed patients with Parkinson's disease (PD), focusing on retirement rates, medical absenteeism, self-perception of disability, as well as motor assessments of parkinsonism, motor fluctuations, and dyskinesias. Thirty full-time-employed PD patients (disease onset before age 60 years) and on optimized monotherapy with LD exhibiting minor motor fluctuations or dyskinesias were entered into a 2-year randomized double-blind placebo-controlled study of ENT adjunctive therapy. The outcome measures were the number of full-time-employed patients at study end, cumulative days of medical absenteeism, patient-completed disability assessments, diary records, and the Unified Parkinson's Disease Rating Scale-based measures of motor fluctuations and dyskinesias. LD + ENT treatment was associated with a lower retirement rate (2 [17%] of 12 vs. 6 [50%] of 12; P = 0.12), lower absenteeism rate (21.5 vs. 43.5 days; P < 0.0001), improved self-perception of disability progression over 2 years (change score 1.0 vs. 4.5; P < 0.0001), and lower scores for both motor fluctuations and dyskinesia assessments compared to LD monotherapy. In this pilot study, LD with ENT adjunctive therapy positively influenced employment rate over 2 years; this effect was associated with reduced motor complications and patient perceptions of stabilized disability.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC02 i1="03" i2="X"><s0>002B17F</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Dyskinésie</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Dyskinesia</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Disquinesia</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Incapacité</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Disability</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Incapacidad</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Perception</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Perception</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Percepción</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Etude double insu</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Double blind study</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Estudio doble ciego</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Placebo</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Placebo</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Placebo</s0><s5>12</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Entacapone</s0><s2>NK</s2><s2>FR</s2><s5>13</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Entacapone</s0><s2>NK</s2><s2>FR</s2><s5>13</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Entacapona</s0><s2>NK</s2><s2>FR</s2><s5>13</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Traitement</s0><s5>14</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Treatment</s0><s5>14</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Tratamiento</s0><s5>14</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Mouvement involontaire</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Involuntary movement</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Movimiento involuntario</s0><s5>41</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Trouble neurologique</s0><s5>42</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Neurological disorder</s0><s5>42</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Trastorno neurológico</s0><s5>42</s5></fC07><fN21><s1>057</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Allemagne</li><li>Russie</li><li>Égypte</li></country><region><li>District fédéral central</li></region><settlement><li>Moscou</li></settlement></list><tree><country name="Allemagne"><noRegion><name sortKey="Korchounov, Alexei" sort="Korchounov, Alexei" uniqKey="Korchounov A" first="Alexei" last="Korchounov">Alexei Korchounov</name></noRegion></country><country name="Égypte"><noRegion><name sortKey="Korchounov, Alexei" sort="Korchounov, Alexei" uniqKey="Korchounov A" first="Alexei" last="Korchounov">Alexei Korchounov</name></noRegion></country><country name="Russie"><region name="District fédéral central"><name sortKey="Bogomazov, Gregory" sort="Bogomazov, Gregory" uniqKey="Bogomazov G" first="Gregory" last="Bogomazov">Gregory Bogomazov</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B11 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 001B11 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:07-0090884
|texte= Employment, medical absenteeism, and disability perception in Parkinson's disease : A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy
}}
| This area was generated with Dilib version V0.6.23. |  |